Clinical Trial

Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 5, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, open label, phase II clinical study intended to include patients with locally advanced gastric adenocarcinoma who have not undergone any treatment and are eligible for surgery. The study aims to evaluate the efficacy and safety of the short course sequential radiotherapy regimen of Disitamab Vedotin combined with S-1 and Sintilimab in neoadjuvant therapy for HER2 expressing locally advanced gastric cancer.
Trial Details
NCT Number NCT06487429
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: RemeGen Co., Ltd.
Conditions Gastric Cancer
Enrollment 28 participants
Start Date 2024-05-08
Primary Completion 2026-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-05